step 1 trial semaglutide 2.4 mg weight loss nejm 2021 SURPASS-2 (NEJM 2021) was the definitive head-to-head: tirzepatide vs 1.0 (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Long-term kidney outcomes of semaglutide

Check out these related posts

Very helpful in helping me stay on track with my weight loss goals

If losing the most weight is the goal, semaglutide is the clear winner

Tirzepatide: Dual-Action Weight Loss Therapy Tirzepatide, found in Zepbound, works on two hormone receptors: GLP-1 (appetite and satiety) GIP (glucose-dependent insulinotropic polypeptide), which plays a role in insulin sensitivity and fat metabolism This dual-action approach often leads to: Greater appetite suppression Enhanced effects on blood sugar regulation Higher average weight-loss outcomes in many patients Because tirzepatide influences more than one metabolic pathway, it may be particularly beneficial for individuals with insulin resistance or metabolic syndrome

10.1016/j.jnutbio.2024.109638 167 ZhongH.XiaoR.RuanR.LiuH.LiX.CaiY.et al (2020)

CTA assay A week before the study start (day 7), rats were single-housed with ad libitum access to chow diet and one bottle of water (food and water were placed in the cage lid so that there was room for two water bottles)